eye problems with glp 1 GLP-1s and Health: What You Need to Know What ODs Need to Know

Battelino T, Bergenstal RM, Rodrguez A, Fernndez Land L, Bray R, Tong Z, et al

Several key areas where further research could better inform future consensus reports were of particular interest to the writing group

Patients choosing microdose should expect a slower, more subtle experience

Medicilon team continues to assist the development of GLP-1 drugs through rigorous design of experiments (DOE), professional R&D technology, standardized project management, efficient communication, etc

Clinical trials show semaglutide (Wegovy) produces average weight loss of approximately 15% over 68 weeks, liraglutide (Saxenda) around 810% over one year, and tirzepatide over 20% in some participants, all combined with lifestyle interventions

The growing telehealth and weight loss programs are increasing access to the GLP-1 drugs